Clinical Cardiology Alert – February 1, 2005
February 1, 2005
View Issues
-
Statins, Rhabdomyolysis, and the FDA
The 6 articles in the December 1, 2004, issue of JAMA represent a detailed overview of drug safety in the United States. The withdrawal of cerivastatin reflects the current situation, and problems with antidepressants in youngsters and, more recently, the identification of adverse reactions with the 3 Cox-2 inhibitors, raise important questions regarding the ability of the FDA to effectively police adverse drug reactions after release of a drug. -
Niacin Plus Statins For Low HDL
The addition of niacin to patients with known coronary artery disease on statins raised HDL cholesterol and reduced atherosclerosis progression. -
Left Ventricular Remodeling With Chronic Right Ventricular Apical Pacing
Chronic apical right ventricular pacing in patients with congenital heart block is associated with late findings consistent with deleterious left ventricular remodeling. -
A New Novel Anti-Arrhythmic Agent
RSD1235 shows promise as an agent for the management of atrial fibrillation. -
Clinical Briefs in Primary Care Supplement
-
Pharmacology Watch: Statins and the Incidence of Rhabdomyolysis
The most commonly prescribed statins have a low incidence of rhabdomyolysis, according to the results a new study of more than 250,000 patients.